☆ 4.7 Meeting Abstract

INTERIM RESULTS OF A PHASE 2 STUDY OF XMAB (R) 5871, A REVERSIBLE B CELL INHIBITOR, IN IGG4-RELATED DISEASE

ANNALS OF THE RHEUMATIC DISEASES (2017)

Get Full Text
Add to Collection

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 76, Issue -, Pages 711-712

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2017-eular.3301

Keywords

-

Categories

Rheumatology

Funding

  1. Genetech/Roche
  2. Xencor

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.